Cagrilintide vs Tirzepatide: Amylin vs GIP/GLP-1 Evidence
Fact-checked by NEXTWAVE PEPTIDES Editorial Team
Direct answer: Cagrilintide and tirzepatide are different molecules with different primary receptor systems and separate clinical programs. Cagrilintide is a long-acting amylin analogue that activates amylin and calcitonin receptor complexes. Tirzepatide is a single peptide agonist of the GIP and GLP-1 receptors. Their published results cannot be treated as a head-to-head comparison because the cited trials used different comparators, durations, doses, populations, and estimands.
The central difference is receptor biology
Amylin receptors are complexes formed by the calcitonin receptor with receptor-activity-modifying proteins. A recent cagrilintide structural study examined the peptide bound to active AMY1, AMY2, AMY3, and calcitonin receptors. That record supports describing cagrilintide as an amylin-related receptor agonist; it does not make it a GLP-1 or GIP agonist.
Tirzepatide is a unimolecular GIP/GLP-1 receptor co-agonist. Its receptor design and clinical evidence should therefore be read separately from cagrilintide, even though both development programs measure some overlapping outcomes.
Evidence map: what can and cannot be compared?
| Comparison field | Cagrilintide | Tirzepatide | Interpretation boundary |
|---|---|---|---|
| Molecular class | Long-acting amylin analogue | GIP/GLP-1 receptor co-agonist peptide | Similar study outcomes do not imply the same mechanism |
| Primary receptor record | Amylin receptor complexes and calcitonin receptor | GIP receptor and GLP-1 receptor | Receptor systems should not be merged into one “metabolic peptide” category |
| Example monotherapy evidence | Phase 2 dose-finding trial, 706 cagrilintide participants plus liraglutide and placebo groups, 26-week primary endpoint | Phase 3 SURMOUNT program with longer trials and different populations | Trial phase, duration, and sample size differ |
| Active comparator in the cited primary trial | Liraglutide, not tirzepatide | Placebo in the cited SURMOUNT-1 analysis | No direct cagrilintide-versus-tirzepatide randomization |
| Defensible conclusion | Each program shows activity under its own protocol | Each program shows activity under its own protocol | Cross-trial percentages do not prove superiority |
The cagrilintide Phase 2 trial randomized 706 participants to cagrilintide dose groups, 99 to liraglutide, and 101 to placebo, with percent weight change at week 26 as the primary endpoint. The cited tirzepatide SURMOUNT-1 report describes a much longer Phase 3 program; its three-year analysis focused on participants with obesity and prediabetes and included a 176-week treatment period.
This independent comparison shows why selecting the largest percentage from each paper would be misleading. The cagrilintide result is anchored to a 26-week dose-finding design, while the tirzepatide record uses a different population, duration, comparator, and endpoint framework.
Comparator and duration change the interpretation
The cagrilintide dose-finding study included multiple cagrilintide groups, a liraglutide group, and pooled placebo groups. Its active-comparator result therefore addresses cagrilintide versus liraglutide under that 26-week protocol. It does not answer cagrilintide versus tirzepatide.
The cited tirzepatide analysis comes from SURMOUNT-1 and follows participants with obesity and prediabetes for 176 weeks, followed by an off-treatment period. That design addresses persistence of outcomes and progression to type 2 diabetes in a defined subgroup. It cannot be placed beside a 26-week cagrilintide dose-finding result as if the two trials shared a clock, comparator, or estimand.
For a defensible indirect comparison, at minimum align population, baseline risk, diabetes status, duration, comparator, endpoint definition, estimand, and handling of missing data. If those fields differ, the result should be described as a cross-study context map rather than a superiority ranking.
Similar outcomes do not imply interchangeable mechanisms
Both programs may report body-weight and gastrointestinal safety outcomes, but shared endpoints are not evidence of shared receptor pharmacology. Cagrilintide's receptor record involves calcitonin-receptor complexes with receptor-activity-modifying proteins. Tirzepatide's record involves GIP and GLP-1 receptors. These differences affect which mechanistic experiments are relevant and prevent findings from one molecule from being assigned to the other.
The same rule applies to assays. A cagrilintide receptor-activation study should identify the receptor complex and cell system. A tirzepatide study should identify GIPR and GLP-1R assay conditions. Calling both readouts “receptor activity” without the receptor identity, pathway, concentration range, and reference ligand removes the information needed for comparison.
What a true head-to-head study would need
A direct comparison would randomize eligible participants within one protocol to cagrilintide and tirzepatide, use the same follow-up schedule, define common endpoints and estimands, and apply the same missing-data rules. It would also specify whether the question concerns monotherapy, combination treatment, or a particular population. Without that structure, separate trial reports can describe each development program but cannot establish direct superiority.
Cagrilintide is not the same as CagriSema
Cagrilintide monotherapy and the cagrilintide-semaglutide combination are separate interventions. Results from CagriSema cannot be silently assigned to cagrilintide alone. The cagrilintide clinical-trials guide separates those records, while the cagrilintide research guide explains the amylin and calcitonin receptor terminology.
For tirzepatide context, the tirzepatide versus semaglutide guide shows how molecule identity and study design constrain comparisons.
Material records remain separate from clinical evidence
A Cagrilintide research material and a Tirzepatide research material each require their own identity, specification, and lot documentation. The GLP-1 Peptides collection groups related catalog records but does not make them mechanistically equivalent. Available lot documents can be reviewed in the NEXTWAVE PEPTIDES COA library.
Research limitations
This article compares published receptor and clinical records; it does not perform an original experiment or a formal network meta-analysis. It does not claim clinical superiority, recommend treatment, or transfer trial results to catalog materials. The cited cagrilintide and tirzepatide trials were not a direct head-to-head study, and their numerical results remain conditional on their own protocols.
Frequently asked questions
Is cagrilintide a GLP-1 peptide?
No. The cited structural evidence describes cagrilintide at amylin receptor complexes and the calcitonin receptor. That differs from tirzepatide's GIP/GLP-1 receptor profile.
Was cagrilintide directly compared with tirzepatide in the cited trials?
No. The cagrilintide Phase 2 study used liraglutide and placebo comparator groups. The cited tirzepatide analysis comes from the separate SURMOUNT-1 program.
Can CagriSema results be used as cagrilintide-only results?
No. CagriSema combines cagrilintide with semaglutide, so the intervention and evidence record differ from cagrilintide monotherapy.
Do trial outcomes verify either catalog material?
No. Clinical protocols do not authenticate unrelated research vials. Each material needs its own identity and lot documentation.